Creative Touch Permanent Makeup and Aesthetics

Panthenol’s three mechanisms in skin are genuinely distinct rather than variations on a single theme. As a coenzyme A (CoA) precursor, it supports the metabolic pathways that drive both keratinocyte and fibroblast function – pantothenic acid deficiency measurably suppresses keratinocyte proliferation and skews differentiation, and calcium pantothenate modulates fibroblast gene expression in a direction consistent with active repair rather than maintenance. As a humectant, it reduces TEWL at concentrations as low as 1% with effects measurable at 30 weeks of consistent use. As an anti-inflammatory, dexpanthenol has a clinical evidence base in atopic dermatitis sufficient to earn a consensus recommendation as both a flare-reduction and topical corticosteroid-sparing agent; a clinical status that positions it above most cosmeceutical “soothing” ingredients.

Panthenol is the provitamin, alcohol form of pantothenic acid (vitamin B5), used in topical formulations because it is more stable and better absorbed through the stratum corneum than pantothenic acid itself. Once inside keratinocytes and fibroblasts, panthenol is oxidised to pantothenic acid, which is then incorporated into coenzyme A (CoA) – the central metabolic cofactor involved in fatty acid synthesis, the citric acid cycle, and the acetylation reactions that regulate gene expression. ^[3] This intracellular conversion is the foundation of all of panthenol’s downstream skin effects: it is not acting topically on the stratum corneum surface but metabolically within the cells that build and maintain it.

The alias situation is worth clarifying directly, as it causes consistent confusion in formulation literature. Panthenol and dexpanthenol refer to the same molecule (D-panthenol, the biologically active enantiomer) used interchangeably in skincare and pharmaceutical formulations. DL-panthenol is the racemic mixture. Pantothenic acid is the vitamin form after oxidation. Calcium pantothenate is the dietary supplement salt form. All convert to pantothenic acid in tissue; all are biologically equivalent at the point of CoA synthesis. The distinction matters for reading research literature accurately – clinical studies use these names inconsistently – but not for formulation or clinical outcome purposes.

Keratinocyte Proliferation and the Differentiation Balance

Pantothenic acid is not optional for normal epidermal function. A 2011 study in the Journal of Pharmacological Sciences (Kobayashi et al.) demonstrated that depleting pantothenic acid from keratinocyte culture medium suppressed proliferation, promoted premature differentiation, and increased apoptosis – effects reversed by pantothenic acid reintroduction. ^[4] The mechanism operates through CoA ; without adequate CoA, keratinocytes cannot sustain the energy metabolism and acetylation reactions that drive active cell division, and the balance tips from proliferation toward differentiation.

This is a clinically meaningful finding. In barrier-compromised skin – post-procedure, atopic-tendency, perimenopausal – the epidermal renewal rate is already reduced, and the differentiation programme is often dysregulated in directions that produce a thinner, less regularly structured stratum corneum. Panthenol supports the proliferative capacity of the basal keratinocyte population that is responsible for producing the replacement cells the barrier needs. It is not accelerating turnover artificially; it is maintaining the metabolic conditions under which normal turnover can proceed.

Fibroblast Activation and Wound Healing

In the dermis, calcium pantothenate modulates fibroblast gene expression in a specific direction. A 2009 gene expression study (Biro et al.) established that calcium pantothenate (20 µg/mL) in proliferating human dermal fibroblasts downregulated fibronectin, transferrin receptor, and several MHC Class I-associated genes, whilst upregulating metabolic and synthetic pathways – a pattern consistent with active repair-phase fibroblast behaviour rather than quiescent maintenance. ^[6] Pantothenate also measurably increased fibroblast proliferation and Ki67 expression (the cell cycle marker), confirming genuine mitogenic activity rather than simply altered gene expression without functional consequence. ^[3]

The wound-healing parallel in the current content is therefore mechanistically accurate, not merely a useful metaphor. Barrier damage produces the same cellular repair demands as a superficial wound: keratinocyte re-epithelialisation, fibroblast migration into the repair zone, ECM deposition. Panthenol supports both cell types through the CoA pathway at exactly the stages where these processes are most metabolically demanding.

A 2023 study in Advanced Healthcare Materials (Panthenol Citrate biomaterial formulation) confirmed that panthenol derivatives promote keratinocyte and dermal fibroblast migration and proliferation through integrin α3 upregulation – the cell-surface receptor that guides keratinocyte movement during re-epithelialisation – producing improved re-epithelialisation and granulation tissue formation in wound models. ^[5] The integrin α3 mechanism specifically – regulating epidermal growth, differentiation, and fibroblast migration – gives panthenol’s wound-healing activity a more precise cellular address than “supports healing.”

Humectant Function and TEWL Reduction

Topically applied panthenol is a humectant: it attracts and retains water within the stratum corneum, reducing transepidermal water loss through a film-forming mechanism at the skin surface. A concentration-dependent clinical study measuring panthenol across 0.5%, 1.0%, and 5.0% formulations found that significant TEWL reduction required at least 1.0% concentration, with effects measurable at 30 weeks of daily use and evident within two hours of a single application in barrier-disrupted skin (post-SLES wash test). library.scconline.org The 0.5% concentration produced no statistically significant TEWL reduction.

This concentration threshold matters for reading product labels. Panthenol appears in many formulations at concentrations below 1%, often as a label-presence ingredient rather than a functionally effective one. Formulations where barrier repair is the stated goal should contain panthenol at 1% or above to deliver the documented TEWL-reduction benefit.

The humectant mechanism is distinct from the cellular CoA mechanism: one operates at the stratum corneum surface, the other within viable keratinocytes. Both contribute to barrier function through different routes, which is why panthenol’s overall barrier benefit is greater than either mechanism alone would suggest.

Dexpanthenol in Atopic Dermatitis: A Clinical Evidence Standard

The most robust clinical evidence base for panthenol is in atopic dermatitis. A 2022 consensus review (Use of Dexpanthenol for Atopic Dermatitis, Seoul National University) established that dexpanthenol improves skin barrier function, reduces acute flare frequency, and has a significant topical corticosteroid (TCS)-sparing effect in mild to moderate AD. ^[1]

The TCS-sparing finding is clinically significant. Topical corticosteroids are effective for acute AD flares but carry risks of skin atrophy, barrier thinning, and rebound flare with prolonged use. An ingredient that reduces the frequency with which corticosteroids are needed – by maintaining barrier function and reducing flare frequency between acute episodes – has a clinical utility well beyond the cosmeceutical “soothing” category. The consensus review positions dexpanthenol as an appropriate maintenance treatment for AD, not merely a supportive adjunct.

This evidence level – a consensus recommendation with TCS-sparing data – makes dexpanthenol one of the few non-prescription topical ingredients with a defined clinical role in a diagnosed inflammatory skin condition rather than a general cosmeceutical claim.